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Abstract
Dystroglycan is a ubiquitously expressed heterodimeric adhesion receptor. The extracellular a-subunit makes con-
nections with a number of laminin G domain ligands including laminins, agrin and perlecan in the extracellular
matrix and the transmembrane b-subunit makes connections to the actin filament network via cytoskeletal linkers
including dystrophin, utrophin, ezrin and plectin, depending on context. Originally discovered as part of the dystro-
phin glycoprotein complex of skeletal muscle, dystroglycan is an important adhesion molecule and signalling scaf-
fold in a multitude of cell types and tissues and is involved in several diseases. Dystroglycan has emerged as a
multifunctional adhesion platform with many interacting partners associating with its short unstructured cytoplas-
mic domain. Two particular hotspots are the cytoplasmic juxtamembrane region and at the very carboxy terminus
of dystroglycan. Regions which between them have several overlapping functions: in the juxtamembrane region; a
nuclear localisation signal, ezrin/radixin/moesin protein, rapsyn and ERK MAP Kinase binding function, and at the C
terminus a regulatory tyrosine governing WW, SH2 and SH3 domain interactions. We will discuss the binding part-
ners for these motifs and how their interactions and regulation can modulate the involvement of dystroglycan in a
range of different adhesion structures and functions depending on context. Thus dystroglycan presents as a multi-
functional scaffold involved in adhesion and adhesion-mediated signalling with its functions under exquisite spatio-
temporal regulation.
Introduction
Dystroglycan was first described as laminin binding pro-
tein from brain [1-3] and also identified as a glycan
component of the dystrophin glycoprotein complex
(DGC) of skeletal muscle, whence it derived its most
commonly used name: dystroglycan [4]. Dystroglycan
comprises two glycoproteins that are post-translationally
cleaved from a single gene (Figure 1A). The extracellular
peripheral membrane subunit a-dystroglycan undergoes
extensive N- and O-linked modifications. The central
mucin-like central region is particularly important for
interactions between a-dystroglycan and laminin G (LG)
module-containing extracellular matrix proteins such as
agrin, perlecan and laminin itself (reviewed in [5]). The
b-dystroglycan subunit is subject to some N-linked gly-
cosylation and is a type 1 transmembrane glycoprotein
binding to the carboxy-terminal domain of a-dystrogly-
can on the extracellular face, and to actin either directly
or indirectly through one of a number of actin binding
proteins, on its intracellular face (Figure 1B). Early
hypotheses concerning the role of dystroglycan were
influenced by its central role in the DGC of skeletal
muscle and the interaction with the spectrin family pro-
tein dystrophin (reviewed in [6]). Mutations in the
DMD gene leading to a complete absence of the dystro-
phin protein product give rise to the fatal X-linked con-
dition Duchenne muscular dystrophy (DMD). The
aetiology of DMD, with its sarcolemmal damage and
necrosis; coupled with the domain structure of dystro-
phin that resembled spectrin led to the idea that dystro-
phin in concert with the DGC performed some sort of
shock absorber role providing mechanical stability to
the sarcolemma to withstand the forces of contraction
and relaxation. This was envisaged to be in a similar
way to that in which spectrin in the erythrocyte sub-
membranous cytoskeleton provided visco-elastic support
to the red blood cell membrane to withstand deforma-
tion during passage through small capillaries see [7] for
a recent review. Whilst this is undoubtedly part of the
role of dystrophin, dystroglycan and the DGC, it is
almost certainly not the only role, and there is now a
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functions for the DGC and dystroglycan in particular
(see below). Other emerging concepts are that dystrogly-
can may not be an obligate heterodimer, in particular
b-dystroglycan may have functions in the absence of
a-dystroglycan: functions in cell polarity, in the nucleus
or in cancer [8-10].
Dystroglycan in disease
We have sought over the last 10 years to unravel some
of the signalling mechanisms associated with the DGC
and with b- d y s t r o g l y c a ni np a r t i cular. Within the 120
residue cytoplasmic region of b-dystroglycan, comprising
almost 25% proline, are over 40 predicted interaction
sites comprising 19 different functional motifs (ELM
prediction [11], Figure 2A). Whilst many of these
remain to have ligands or functions ascribed, two parti-
cular clusters of overlapping motifs, one spanning the
extreme C-terminal 6 amino acid residues of b-dystro-
glycan, and the other covering the 10 juxtamembrane
residues of the cytoplasmic region (Figure 2B, C) have
received particular attention. In the following pages we
will focus on the regulation and consequences of these
overlapping motifs for dystroglycan function in the cell.
H o w e v e ri no r d e rt op l a c es o m eo ft h e s ef i n d i n g si n
context it is worth considering the broader role of dys-
troglycan in disease and signalling related to such
diseases.
As a cell adhesion molecule dystroglycan performs
two basic functions: as a physical connection between
extracellular matrix and cytoskeleton, and as a transdu-
cer of signals from outside to inside, so called ‘outside
in signalling’ (see below). Whatever ones belief in the
contribution of either of these functions to normal or
disease processes, it remains difficult to dissect function-
ally the mechanical adhesion component from the sig-
nalling component, indeed they probably are
Figure 1 A, a simple schematic representing the a-/b-
dystroglycan pro-protein and subsequent cleavage to a- and
b-dystroglycan. B. Organisation of a- and b-dystroglycan at the cell
membrane showing topology and major interactions.
Figure 2 A. Summary of ELM output for b-dystroglycan cytoplasmic domain. Horizontal grey lines represent the primary sequence of the
dystroglycan cytoplasmic domain, pink bars are low complexity and orange bars are disordered regions, blue and red boxes represent the
position(s) of specific linear motifs as described on the left. Numbers represent the number of occurrences of each motif in the sequence, full
annotation can be found at http://www.elm.eu.org. B Scheme showing detail of sequence and position of interaction sites in the b-dystroglycan
juxtamembrane region including Rapsyn, ERM, ERK and NLS. C Scheme showing detail of sequence and position of interaction sites in the b-
dystroglycan carboxy terminus including WW SH3 and SH2. X denotes any residue within the ELM consensus, and pY represents phosphorylated
tyrosine.
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tend to be ascribed to mechanical or signalling func-
tions. As alluded to above, a mechanical role for the
DGC in muscle, of which dystroglycan is an essential
core element, initially held sway, but this has been sup-
planted to a certain extent by signalling roles (reviewed
in [12-14]). We shall discuss some of the signalling
function that is directly associated with dystroglycan in
later sections, but it is also worth noting that the DGC
as a whole acts as a signalling scaffold for pathways that
are not directly mediated through dystroglycan. Exam-
ples of these include nitric oxide synthase (NOS) signal-
ling, Pi3-kinase and Akt-mediated survival signalling
and pathways involving small and heterotrimeric G-pro-
teins, mediated variously through dystrophin, dystrobre-
vin and syntrophins, for examples see [15-19]. Although
in muscle there appears to be only one DGC, there
must be spatio-temporal regulation of these signalling
functions through mechanisms that remain to be eluci-
dated, as it seems unfeasible that they could all operate
simultaneously through the same complex. But besides
these signalling roles that would clearly be perturbed if
the integrity of the DGC were compromised due to
changes in dystroglycan, there are more direct changes
in dystroglycan function that would intuitively appear to
have a more mechanical function. Disease associated
with this latter scenario are termed the dystroglycanopa-
thies, and arise not through mutations in dystroglycan
itself, but in a number of genes that are known or
presumed to have function in the glycosylation of dys-
troglycan [[20][Muntoni, 2007 #2825]]. These glycosyl-
transferase genes are responsible for the essential post-
translational modifications of a-dystroglycan that are
required for LG module binding, and without this glyco-
sylation, dystroglycan is functionally unable to connect
to the extracellular matrix. This can result in very severe
disease involving both muscle and neurological pheno-
types such as in Fukuyama and congenital muscular
dystrophy 1D, muscle eye brain disease or Walker War-
burg syndrome. These phenotypes also highlight another
area of significant involvement of dystroglycan function,
namely in the neuronal system, with functions in neuro-
nal cell migration and patterning as well as neuronal
cell adhesion, brain architecture and neuronal signalling.
A discussion of this is beyond the scope of this review
and readers are directed to more authoritative sources
[21].
Dystroglycan as an adhesion receptor
in muscle and non-muscle tissues:
the carboxy-terminal region
Dystroglycan is ubiquitously expressed and consequently
found to have critical roles in a variety of situations
where cell adhesion is important. In development, the
laminin binding activities of dystroglycan are crucial for
early embryonic basement membrane formation, to the
extent that mice null for dystroglycan fail to properly
assemble Reichert’s membrane, the first extra-embryonic
basement membrane, resulting in a failure in implanta-
tion and early embryonic lethality [22]. Branching
epithelial morphogenesis in lung and kidney, and prob-
ably other glandular epithelial tissues that form by a
similar process, is also reliant on dystroglycan function
(reviewed in [23,24]) as is the development and mainte-
nance of many neuronal structures. Various clinical con-
ditions and experimental and model systems have
revealed roles for dystroglycan in neuronal migration,
the blood brain barrier, retinal layering, Schwann cell
wrapping and the architecture of the nodes of Ranvier
[21,25]. Notwithstanding the ubiquitous distribution and
multiple roles in multiple tissues, it remains that dystro-
glycan has been studied most extensively in muscle, and
in particular in relation to its role in the dystrophin gly-
coprotein complex and associated muscular dystrophies.
From the point of view of muscle, dystroglycan has a
role in all stages of muscle development, and is clearly
identified in the developing myotome, as well as in
migratory myoblasts [26] where it plays an important
role in organising laminin 111 [27]. A role for dystrogly-
c a ni na d h e s i o ni nm i g r a t o r ym y o b l a s t sa n dm o r e
mature ‘static’ myofibres highlights the versatility of this
adhesion receptor and points to multiple modes of
interaction and regulation. One commonly used
mechanism for regulating adhesion-dependent processes
is tyrosine phosphorylation. Tyrosine phosphorylation of
b-dystroglycan in response to cell adhesion has been
recognised for some time as an important molecular
switch to govern dystroglycan function in relation to
dystrophin and utrophin binding [8,28]. This concept
has been further extended recently by the identification
of phospho-tyrosine mediated regulation of b-dystrogly-
c a nf u n c t i o ni nb o t hp o d o s o m e sa n df o c a la d h e s i o n
structures (Figure 3), in addition to its established func-
tion in the costameric adhesion structures of skeletal
muscle [13].
A number of studies utilising non-muscle cells, myo-
blasts and myotubes had identified tyrosine 890 of b-
dystroglycan (Y890 in mouse, Y892 in humans) as a tar-
get for phosphorylation by Src and other Src family
kinases, and furthermore that Y890 phosphorylation reg-
ulates the interaction between dystroglycan and key cel-
lular binding partners, most notably dystrophin and
utrophin [28-32]. Considering dystroglycan as a cell
adhesion molecule, with regulation by tyrosine phos-
phorylation; we have investigated dystroglycan function
in light of the integrin paradigm. Binding of extracellular
matrix proteins to integrins causes allosteric changes
across the plasma membrane resulting in the binding of
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phosphorylation and the establishment of multiprotein
signalling complexes on the intracellular face, so called
outside-in signalling (see [33] for recent review). Integ-
rins constitute a large family of cell adhesion receptors
found in many cell types and tissues. Integrins make
connections with extracellular matrix proteins and
cytoskeletal components, and they are all capable of sig-
nalling via tyrosine kinases (reviewed in [34,35]).
Depending on the cell, the extracellular matrix ligand
and the particular combination of a-/b-integrin hetero-
dimers, different signalling complexes are assembled
leading to different intracellular responses. Unlike the
multitude of integrin heterodimer combinations with
different cell and tissue distributions however, there is
only one ubiquitously expressed a-/b-dystroglycan het-
erodimer. Therefore integrins are represented in multi-
ple genes giving rise to multiple functions, whereas
dystroglycan is represented by one gene but is still cap-
able of mediating multiple functions. In the case of dys-
t r o g l y c a ni np a r t i c u l a rw eh ave focussed our attentions
on the cytoplasmic domain of b-dystroglycan and the
myriad of predicted protein-protein interaction sites that
could be involved in mediating these multiple functions
Figure 3 Cartoon of adhesion types found in myoblasts and myofibres. Grey represent the cell membrane, red represents actin filaments,
green myosin filaments, dark grey balls dystroglycan containing adhesions, black bars labelled Z are the Z-discs of striated muscle and the
extracellular matrix is represented by the blue-grey gradient at the bottom.
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function and the potential interactions mediated
through these sites in the context of adhesion-mediated
signalling. Dystroglycan engagement by laminin results
in the phosphorylation of the cytoplasmic region of b-
dystroglycan with the site being unequivocally identified
as tyrosine 890 [29,31]. Not only was dystroglycan a
substrate for adhesion-mediated tyrosine phosphoryla-
tion in a manner analogous to integrins, but also the
tyrosine phosphorylation of dystroglycan at Y890
resulted in the disruption of the C-terminal WW
domain interaction site for both utrophin and dystro-
phin (Figure 2C) [28-30]. Interestingly however, caveo-
lin-3 binding to this same site via a WW-like domain
[36] appeared insensitive to the tyrosine phosphorylation
[28]. Therefore extracellular signals were sufficient to
generate a phosphotyrosine signal which acts as a mole-
cular switch subsequently altering the binding of dystro-
glycan to two of its major ligands connecting it to the
actin cytoskeleton, no different to outside-in signalling.
The kinases responsible for the phosphorylation of dys-
troglycan was subsequently demonstrated to be Src and
other Src family members [31], also key integrators of
integrin-mediated adhesion signalling. In addition to the
interaction between dystroglycan and dystrophin or
utrophin, other cytolinker proteins such as plectin have
also been demonstrated to make interactions with dys-
troglycan, and may also have a compensatory and pro-
tective role in situations where dystroglycan function is
partly compromised such as in the mdx mouse [37].
Whether there is direct competition for binding to dys-
troglycan between plectin and dystrophin in vivo is not
clear, but biochemically, binding sites on dystroglycan
for the two proteins do overlap, and in the absence of
dystrophin, such as in the mdx mouse, the organisation
of plectin and dystroglycan in the sarcolemma does
change [37]. A further competitive interaction is that
between the signalling adapter Grb2 and dystrophin.
Grb2 binds to the SH3 domain interaction motif (PxxP)
that overlaps the WW domain binding motif (PPPY;
Figure 2C) in dystroglycan [38-40], and although at the
biochemical level the interaction is clearly competitive,
the functional significance of any Grb2 interaction with
dystroglycan in cells and tissues remains unclear. From
studies in Drosophila there appears also to be competi-
tive interactions for dystroglycan, but rather than the C-
terminal WW domain motif being the focus of interac-
tions a non-overlapping SH3 motif located more amino-
terminally is functionally more important for such func-
tions as polarity determination [41]. Nonetheless the
WW domain interaction site is essential, though due to
the presence of a second WW domain interaction site
that can also mediate interactions through dystroglycan,
is partially redundant [42]. It should be noted however,
that compared to the almost 95% identity between ver-
tebrate dystroglycan cytoplasmic regions, Drosophila
dystroglycan is considerably more divergent [43].
Antibodies directed against a-dystroglycan and b-dys-
troglycan readily recognise both proteins in the sarco-
lemma and more precisely in costameres of striated
muscles. However in the analogous focal adhesion struc-
tures of fibroblast or myoblast cells for example, only
the extracellular epitopes of a-dystroglycan are detect-
able by antibody staining [44,45]. As a- and b-dystrogly-
can are believed to be obligate heterodimers it has
therefore been assumed that whilst b-dystroglycan was
not detectable in focal adhesions by antibody staining or
using GFP-fusions, that it is nonetheless present. It has
been hypothesised that the cytoplasmic region of b-dys-
troglycan is in an environment subject to considerable
‘molecular crowding’ or ‘epitope masking’,ap h e n o m -
enon seen with other focal adhesion proteins such as a-
actinin [46], rendering it undetectable by routine visuali-
sation techniques. Despite its ‘presumed presence’ the
inability to detect or visualise dystroglycan in other
classes of adhesion has hampered further investigation
in this area. Recently significant inroads have been made
into this problem, with the finding that dystroglycan is a
component of podosome adhesion structures, and tech-
niques have been developed to visualise dystroglycan in
focal adhesions making the study of dystroglycan in
these adhesion types more amenable [47,48].
From work investigating the role of dystroglycan in
adhesion structures it is clear that DG can play a part in
regulating the type and abundance of such structures
within a cell. Over-expression of tagged dystroglycan
results in a relative increase in the levels of focal com-
plexes and a decrease in fibrillar adhesions compared to
other cellular adhesions whereas shRNA knockdown of
dystroglycan causes the reverse effect [48]. The mechan-
ism of action of dystroglycan in this case is not known,
but a candidate to mediate this effect may be vinexin
recruitment. Dystroglycan has been shown to interact
with vinexin, a vinculin binding partner that resides in
focal adhesions. This binding occurs between the 3rd
SH3 domain of vinexin and the proline rich C-terminal
region of b-dystroglycan, specifically the most C-term-
inal SH3 binding domain [48] (Figure 2C). Dystroglycan
shRNA knockdown myoblast cells spread poorly on E3
laminin (a dystroglycan specific ligand), but can be res-
cued through overexpressing dystroglycan. However,
overexpression of a construct mutated in the vinexin-
b i n d i n gs i t ei su n a b l et or e s c u et h i sc e l ls p r e a d i n g
defect. Therefore, the interaction between vinexin and
dystroglycan, and possibly vinculin too, can modulate
cell spreading. The interaction of a vinexin SH3 domain
with the C-terminal SH3 motif in dystroglycan also
highlights a further potential competitive interaction.
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interaction with dystroglycan was sensitive to Y890
phosphorylation [48], just as the binding of utrophin or
dystrophin to this region are prevented by tyrosine
phosphorylation [29,30]. However as both vinexin and
utrophin bind the same region when not phosphory-
lated, there could be direct competition between the
two proteins for the SH3 motif to which vinexin binds
and the overlapping type 1 WW domain motif to which
utrophin binds (dystrophin is not present in myoblasts;
see Figure 2C), rather than Src modulated phosphoryla-
tion-dependent switching for this site.
Another adhesion type where dystroglycan has
recently been found to play a role is the podosome. In
podosomes however, there does appear to be Src-
mediated Y890 phosphorylation-dependent switch [47].
Podosomes are a less dense arrangement of adhesion
proteins around an actin core (Figure 3), most often
observed in normally migratory cells and invasive cells
including tumour cells. The looser arrangement of pro-
teins in the podosome may have facilitated the accessi-
bility of dystroglycan antisera making the visualisation
of dystroglycan in podosomes more straightforward than
in focal adhesion like structures. Moreover the observa-
tion that dystroglycan in podosomes is phosphorylated
on Y890 also precludes some of the binding partners
that might occupy the C-terminal residues, such as
vinexin or utrophin for example. However, Y890 phos-
phorylation does then generate an SH2 domain ligand
[31], to which Src itself can bind [31,47] along with
which it recruits Tks5 to podosomes [47]. In an analo-
gous manner to dystroglycan in focal adhesions, the
levels of dystroglycan in the cell and the switching of
dystroglycan function, in this case by Src-mediated
phosphorylation of Y890 to generate a ternary dystrogly-
can:Tks5:Src complex, can regulate the formation of
podosomes in myoblasts [47] (Figure 4). Accordingly,
dystroglycan in concert with integrins, is involved in the
spatial and temporal remodelling of adhesion numbers,
types and distribution. Through this dystroglycan there-
fore plays an important role in effecting changes in
myoblast anchorage, motility and migration and conse-
quently facilitates the differentiation process and the
establishment of costameric adhesion structures in
mature myofibres.
The juxtamembrane region: Rapsyn, ERM
proteins, ERK signalling and nuclear localisation
Transient overexpression of dystroglycan-GFP in the
majority of cells in culture is associated with the appear-
ance of numerous filopodia and microvilli like struc-
tures. Concomitant with the formation of these
structures is a dramatic rearrangement of the actin
cytoskeleton from the typical orthogonal array of stress
fibres to a more peripheral band of actin cables and
actin-containing microvilli and ultimately in the most
extreme cases an apparent total dissolution of the stress
fibre network and the appearance of numerous fine filo-
podia and dorsal microvilli-like structures rich in dystro-
glycan-GFP [49]. Biochemical analyses of the
dystroglycan cytoplasmic domain in isolation, revealed
that it had intrinsic actin binding and bundling proper-
ties, which could in part account for the ability of dys-
troglycan to induce the formation of actin bundles at
the cell membrane and drive filopodia formation [49]. A
series of deletion constructs of dystroglycan which
removed all of the major domains of a-o rb-dystrogly-
can in turn and in combination, revealed that the cyto-
plasmic domain of b-dystroglycan was both necessary
and sufficient for filopodia formation providing that it
was targeted to the plasma membrane either by secreted
alkaline phosphatase-tags or by myristoylation sequences
targeting it to the inner membrane leaflet [49,50].
A manual search of the sequence of the cytoplasmic
domain of dystroglycan revealed a stretch of basic resi-
dues in the juxtamembrane region (Figure 2B) that
resembled similar sequences in a number of other cell
adhesion receptors (CD44, ICAM-1, ICAM-2 and L-
selectin) that are able to interact with ezrin, radixin,
moesin (ERM) family proteins [51-54]. In most cases
the recruitment of activated ezrin to these cell adhesion
receptors has been reported to induce the formation of
microvilli structures [51,53,54], dystroglycan would also
appear to be no exception in this regard. Deletion or
alteration of the character of these sequences in dystro-
glycan was sufficient to prevent the association of ezrin
with dystroglycan and prevented dystroglycan-induced
actin-rich protrusions [50,55]. The co-localisation of
endogenous dystroglycan and ezrin in microvilli-like
structures and co-immunoprecipitation and GST-pull-
down of dystroglycan and ezrin from cell extracts sug-
gest a direct role for dystroglycan in the formation of
microvilli-like structures [49,55]. Moreover, the dystro-
glycan-dependent and ezrin-dependent formation of filo-
podia also required the activation of Cdc42, as dominant
negative Cdc42 prevented the dystroglycan-dependent
microvilli formation and the dystroglycan-dependent
recruitment of ezrin to the actin cytoskeleton [49,55].
Depletion of dystroglycan levels by RNAi also had an
inhibitory effect on the ability of active Cdc42 to induce
filopodia, indicating a central role for dystroglycan in
the formation of filopodia in response to Cdc42 [50].
ERM family proteins have been demonstrated pre-
viously to interact with components of the Rho GTPase
signalling machinery, notably RhoGDI [56] and the GDP/
GTP exchange factor (GEF) for Cdc42 and Rho: Dbl
[57,58]. An interaction between dystroglycan, ezrin and
regulatory elements of the Rho GTPase signalling
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podia formation. We identified a dystroglycan-Dbl-ezrin
complex by a combination of immunoprecipitation,
tagged protein pulldown and immunofluorescence
microscopy. Furthermore we demonstrated that the tar-
geting of a dystroglycan-Dbl-ezrin complex to the mem-
brane promoted the formation of filopodia and microvilli
by the local activation of Cdc42 at the membrane. Mislo-
calisation of the dystroglycan-Dbl-ezrin complex to the
cytoplasm by using a cytoplasmic dystroglycan construct
had a dominant-negative effect on filopodia formation
[50]. Thus the peripheral membrane localisation of dys-
troglycan is again essential for its function as a scaffold
for components of the actin-signalling machinery to pro-
ductively generate new actin-based structures such as
filopodia and microvilli which could also be important
prerequisites for adhesion formation.
In addition to being a substrate for adhesion-mediated
signalling, dystroglycan was also found to have an antag-
onistic role in other signalling cascades mediated by
integrins. Most notably it has been demonstrated that
integrin a6b1 and dystroglycan have antagonistic roles
in signalling to the Ras-Raf-MEK-ERK (ERK) pathway,
with dystroglycan having an inhibitory effect on integ-
rin-mediated activation of the ERK pathway [59]. Dys-
troglycan function is also required, independently of
integrin function, for laminin 311 mediated stretch-acti-
vated ERK signalling in alveolar epithelial cells [60]. The
dystroglycan cytoplasmic region has predicted ERK
MAPK binding sequences in the juxtamembrane region
(Figure 2C) and through a combination of yeast-two
hybrid and proteomic analyses components of the ERK
pathway were found to interact with the cytoplasmic
region of b-dystroglycan; both MEK and activated ERK
Figure 4 Cartoon summary of different dystroglycan functions/complexes in myoblasts top or myofibres bottom referred to in the
main text. Grey represent the cell membrane, red represents actin filaments, green myosin filaments, black Z-discs of striated muscle, dark blue
ellipse is the nucleus and all pale blue represents different dystroglycan-containing structures according to the numbers. 1, normal costameric
adhesions containing the dystrophin-dystroglycan glycoprotein complex. 2, mdx costameric adhesions with compromised connectivity to the
underlying z-discs, containing plectin-dystroglycan and utrophin-dystroglycan complexes. 3. Neuromuscular junction (NMJ) containing;
dystrophin-dystroglycan glycoprotein, utrophin-dystroglycan and rapsyn dystroglycan complexes 4. Myotendinous junction (MTJ) containing
utrophin-dystroglycan complex. 5. Focal adhesions containing dystroglycan vinexin and possibly dystroglycan utrophin complexes. 6. Podosomes
and invadopodia containing dystroglycan Tks5 and dystroglycan-Tks5-Src complexes. 7. Focal contacts containing dystroglycan vinexin
complexes. 8. Filopodia containing dystroglycan-ezrin and dystroglycan-ezrin-Dbl complexes. 9. Nuclear dystroglycan in complex with other
dystrophin associated proteins including Dp71. 10. Dystroglycan ERK complexes directing ERK signalling to nucleus or cytoplasm. * represents
the possibility for regulation of the complex at this site by tyrosine phosphorylation.
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was affected by binding to dystroglycan, nor was dystro-
glycan a substrate, but surprisingly the localisation of
dystroglycan with MEK or active ERK was quite differ-
ent within the cell [45]. Active ERK localised to focal
adhesions as had been demonstrated previously [61],
where it colocalised with a-dystroglycan, whereas MEK
was colocalised with b-dystroglycan in membrane ruffles
[45]. This differential spatial localisation of two compo-
nents of a canonical signalling cascade could provide a
potential explanation for the antagonistic role of dystro-
glycan in opposing integrin-mediated ERK activation as
above. A further development of this idea has been put
forward, whereby scaffolds such as dystroglycan are
important integrators of ERK signalling, in that they
direct ERK signalling to or away from the nucleus by
acting as dimerisation sites for ERK activation [62]
reviewed in [63]. Such a mechanism could explain the
role of dystroglycan in integrin-mediated ERK signalling
[59], whilst at the same time allowing a dystroglycan-
dependent activation of ERK signalling [60] depending
on whether the downstream target was nuclear or cyto-
plasmic [63].
One intriguing possibility that arises from the role of
the juxtamembrane region in what appear to be dispa-
rate functions: ERM-mediated actin cytoskeleton remo-
delling and ERK signalling, is the additional
observation that the same region is also involved in
nuclear targeting of dystroglycan [64]. Whilst the func-
tion of dystroglycan in the nucleus and the precise
mechanism whereby it is targeted to the nucleus is
unresolved it is interesting to consider this in the con-
text of ezrin and ERK, proteins which are also targeted
to the nucleus. ERM proteins and the related protein
merlin are trafficked to the nucleus in a cell density/
and or cell cycle-dependent manner [65,66]. Merlin
can regulate the activity of ERK, and ERK and merlin
nuclear translocation are stimulated by cell adhesion
[65]. Given the interdependence in regulation of ERK
by dystroglycan and or merlin (and possibly other
ERM proteins) and that the NLS in dystroglycan is
also the site of ERM or ERK interaction (Figure 2B) it
is possible that ERK or ERM proteins might target dys-
troglycan to the nucleus but not vice versa. But what is
the function of dystroglycan in the nucleus? The
observations from the Cisneros lab would suggest
there are separate nuclear dystroglycan complexes,
containing dystroglycan and the short dystrophin iso-
form Dp71 and other dystrophin-associated proteins
(DAPs), and that these may contribute to the nuclear
cytoskeleton or nuclear membrane/cytoskeleton inter-
face [67-69] in a manner analogous to the role of dys-
troglycan in the sarcolemma. Whether dystroglycan
and any complexes it may form in the nucleus have a
general role in nuclear architecture as might be sug-
g e s t e db yt h ep r e s e n c eo fD A P s ,o rt h ep r e s e n c eo f
dystroglycan in the nucleus is more dynamic and has
some sort of regulatory function has yet to be estab-
lished. More recent evidence from the Cisneros group
suggests that there may be dynamic control of dystro-
glycan nucleocytoplasmic shuttling mediated by impor-
tins (Bulmaro Cisneros personal communication), but
function still remains to be elucidated.
A further role for the juxta-membrane region of b-
dystroglycan is in binding to the neuromuscular junc-
tion (NMJ) protein rapsyn [70]. Dystroglycan and rap-
syn are essential for the agrin-mediated clustering of
acetylcholine receptors at the NMJ [71,72], where they
form a specific complex with utrophin even in mature
muscle fibres (see [73] and reviews in [74,75]). The
RING-H2 domain of rapsyn appears to be responsible
for the interaction with dystroglycan [76], and clearly
given the separation from the C-terminal WW binding
motif to which utrophin could bind, these two interac-
tions could be simultaneous. But how the rapsyn-dys-
troglycan interaction in this region is accommodated
in the face of potential competing interactions between
ezrin and ERK remains to be tested. Furthermore,
whilst binding to rapsyn is not in question, a role for
ERM proteins in mediating acetylcholine receptor clus-
tering through the same site has not been ruled out.
Another dystroglycan interaction that has been charac-
terised at the molecular level also occurs at synapses,
though in this instance in the hippocampus. S-SCAM,
also known as MAGI-2, itself a scaffold protein in
inhibitory synapses in the hippocampus [77], interacts
with dystroglycan at the N-terminal type 1 WW
domain interaction motif [78] (Figure 2). To date S-
SCAM is the only protein to be identified to bind to
this region of dystroglycan. The precise role of dystro-
glycan in binding to S-SCAM, and how this impacts
on S-SCAM functions as a scaffold to activate RhoA
protein in response to NMDA receptor signaling in
dendrites [79], is not clear.
Conclusions
From our own studies and those of others it is clear that
dystroglycan can form a range of multiprotein complexes
in the cell; as a component of adhesions in the DGC of
skeletal muscle, in focal adhesions and in podosomes, as
a scaffold and regulator for the ERK MAP kinase cascade,
as a dystroglycan-Dbl-ezrin complex involved in the reg-
ulation of the actin cytoskeleton, and as yet to be defined
role in the nucleus (Figure 4). The role of dystroglycan
and how it is regulated both spatially and temporally to
maintain these apparent separate functions remains to be
fully elucidated. One clear mechanism of modulation is
through tyrosine phosphorylation acting as a molecular
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glycan and hence control its function. In this regard the
dystroglycan-Src axis appears to be central to the control
of dystroglycan function at least as far as cell adhesion is
concerned (Figure 5 and additional file 1). There is still
much to learn about this enigmatic protein. One emer-
ging area is the role of dystroglycan in cancer. Dystrogly-
can function appears to be disrupted in numerous
epithelial derived cancers [9,80,81] though the precise
functional role of dystroglycan in this context is not
clear, but probably involves aspects of both cell adhesion
and cell migration, and possibly its putative nuclear func-
tion. Furthermore, studies in Drosophila have revealed a
role for dystroglycan in both apico-basal and anterior-
posterior cell polarity [43,82-84]. It is therefore very likely
that the multifunctional adaptor role of the dystroglycan
cytoplasmic region will lead to the identification of other
interactions and distinct dystroglycan complexes in
others systems.
Additional file 1: Animated Powerpoint version of Figure 5.
Interaction map for some of the dystroglycan cytoplasmic domain
interacting proteins discussed in this review. A. Individual named
proteins are represented as circles (caveolin-3; Cav-3, dystroglycan; DG)
with binding interactions between each them represented by green
lines. Competing and regulatory interactions or mutually exclusive
interactions are represented by red lines, e.g. phosphorylation of DG by
Src prevents utrophin or dystrophin binding so a red line is drawn
between Src and utrophin or dystrophin, Caveolin-3 and dystrophin both
bind to and compete for the same site on DG, so a red line is drawn
between them. Focal adhesion interactions are outlined in blue,
podosome interactions are outlined in yellow and costameric
interactions in magenta. The overlay of all of these interaction groups
highlights the central role of the DG-Src axis in acting as a molecular
switch to control the various functions and interactions of dystroglycan.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1478-811X-8-3-
S1.PPT]
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